A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a

Clinical trial NCT01724021 · COMPLETED

Trial details

NCT number: NCT01724021
Sponsor: Hoffmann-La Roche
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma

Start date: 2012-12-01
Primary completion: 2015-01-01
Enrollment: 743

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.